Regulatory in Thoughts from the Centre

Five strategies that could help biopharma firms get more ROI bang for their R&D buck

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Pharma

This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on the findings from our 2018 Measuring the return from pharmaceutical innovation 2018 report, and what strategies pharma can use to improve their return on investment from R&D.

Continue reading

Posted on 01/02/2019 | 0 Comments

The future awakens: how have our life sciences predictions fared in 2018

By Karen Taylor, Director, Centre for Health Solutions

Blog

Last week we provided an update on the three health care predictions from our November 2017 report - The future awakens: Life Sciences and health care predictions 2022. As promised, this week’s blog reviews developments during 2018 on the three predictions that are more life sciences focused and what we might expect to see in 2019.

Continue reading

Posted on 25/01/2019 | 0 Comments

Patient access to innovative medicine in Europe: A collaborative and value-based approach

By Elizabeth Hampson, Director, Monitor Deloitte and Amen Sanghera, Centre for Health Solutions

Market

This week, we launched our report Patient access to innovative medicine in Europe: A collaborative and value-based approach, which examines the challenges European payers and the pharma industry are facing in funding and bringing the latest innovations to market. Moreover, the report also looks at how key industry stakeholders can work in innovative ways to ensure patients have access to the latest medical innovations.

Continue reading

Posted on 11/01/2019 | 0 Comments

My Take: Highlights from the 2018 FT Conference panel discussion on the potential for a successful life sciences economy in the UK

By John Haughey, Deloitte Industry Leader, Life Sciences & Health Care

Regulatory

Earlier this month I had the pleasure of chairing a panel of life science experts at the Global Financial Times Pharmaceutical and Biotechnology conference.1 The conference brought together some of our industry’s leading minds to discuss the commercial conundrums of disease prevention, the transformational impact of advanced gene and cell therapies and the hope and hype of patient-centricity. The discussion topic for my panel was - ‘Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy’, and was focused on the UK’s Industrial Strategy and in particular the UK’s sector deal for life sciences.2 In this week’s blog I wanted to share some of my key takeaways from our animated and insightful discussion.

Continue reading

Posted on 30/11/2018 | 0 Comments

A bold future for life sciences regulation: Predictions 2025

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.

Continue reading

Posted on 08/11/2018 | 0 Comments

Keep calm and carry on: How can the healthcare and life sciences industries weather the Brexit storm?

Compass

We have now had the best part of a week to absorb the momentous news that the UK has voted to leave the European Union. Much has been written about this seismic event and, following our blog in February this year, on what Brexit might mean for the healthcare and life sciences industries,i we thought we should use this week’s blog to update our views on the potential risks and opportunities for our life sciences and healthcare sectors.

Continue reading

Posted on 01/07/2016 | 0 Comments

What would Brexit mean for the pharma industry?

Bzi_foc_glb_ho_2237

The Conservatives' 2015 election manifesto committed to hold a referendum by 2017 on whether or not the UK should stay in or leave the European Union. Increasing unrest among Eurosceptic politicians and a narrowing of the polls on the likely outcome of the vote has led to the suggestion that the referendum could be held as early as June or September 2016. While all industries are speculating on the potential impact of an “out” vote, the global pharmaceutical industry faces some very specific concerns. This blog considers some of the main questions that the pharmaceutical industry is contemplating as part of the in/out debate.

Continue reading

Posted on 12/02/2016 | 1 Comments

New European clinical trials regulation - Are you ready?

Ind_lsh_glb_ho_2178

This week we're delighted to feature a guest blog written by Fiona Maini and Sarah Chan who both work in Deloitte's Risk Advisory practice. The focus is on the new clinical trials regulation and what it means for Life Science companies.

Continue reading

Posted on 28/08/2015 | 0 Comments

Insights from King’s Fund report on NHS performance under coalition government

Ind_lsh_glb_ho_1317_hi

This week the Kings Fund published its report 'The NHS under the coalition government'. This report examines the NHS’s performance between 2010 and 2015, based on routinely available data (inputs such as funding and staffing and outputs such as hospital admissions and A&E attendances). It also draws on surveys of patient and staff experience; data on access and waiting times targets; and measures of safety and quality of care. The report concludes with an analysis of NHS productivity and an assessment of its prospects in the next parliament and beyond.

Continue reading

Posted on 27/03/2015 | 0 Comments

Risk and Regulation: A wave of change for pharma

Env_glb_ho_1937

This week the Center for Health Solutions is delighted to bring you a guest blog from one of our regulatory compliance specialists in health care and life sciences:

Continue reading

Posted on 30/07/2014 | 0 Comments